CN106983871A - A kind of preparation method of large biological molecule compound stable state quercetagetin - Google Patents

A kind of preparation method of large biological molecule compound stable state quercetagetin Download PDF

Info

Publication number
CN106983871A
CN106983871A CN201710206621.9A CN201710206621A CN106983871A CN 106983871 A CN106983871 A CN 106983871A CN 201710206621 A CN201710206621 A CN 201710206621A CN 106983871 A CN106983871 A CN 106983871A
Authority
CN
China
Prior art keywords
quercetagetin
zeins
propylene glycol
biological molecule
glycol alginate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710206621.9A
Other languages
Chinese (zh)
Inventor
高彦祥
孙翠霞
代蕾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Agricultural University
Original Assignee
China Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Agricultural University filed Critical China Agricultural University
Priority to CN201710206621.9A priority Critical patent/CN106983871A/en
Publication of CN106983871A publication Critical patent/CN106983871A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a kind of preparation method of large biological molecule compound stable state quercetagetin, the transmission system technical field belonged in function factor stable state technology.This method is using zeins and propylene glycol alginate as raw material, using quercetagetin as bioactive substance, the zeins propylene glycol alginate large biological molecule compound of load quercetagetin is prepared using anti-solvent coprecipitation, the wherein mass ratio of zeins and propylene glycol alginate is 40:1~1:10, the addition of quercetagetin is 0.1wt%~2.0wt%.The macromolecular complex is after drying in spongy, significantly increase the water solubility of quercetagetin, the embedding rate of quercetagetin more than 90% and 6% 15% load capacity are realized, its light degradation and thermal degradation speed is effectively reduced, hence it is evident that improve its bioavailability.The implementation of the present invention can provide new approaches and new way for function factor stable state.

Description

A kind of preparation method of large biological molecule compound stable state quercetagetin
Technical field
The invention belongs to the transmission system technical field in function factor stable state technology, and in particular to a kind of biological big point The preparation method of sub- compound stable state quercetagetin.
Background technology
Quercetagetin is as a kind of polyhydroxy flavone compound, with anti-oxidant, anticancer, anti-inflammatory, antibacterial, disease-resistant The various biological such as poison function and pharmacological action, can effective prevention of cardiovascular disease, significantly improve body immunity.However, Quercetagetin is insoluble in water, sensitive to light, heat, oxygen, easily degrades, bioavailability is low, hence it is evident that limit its Application in field of food.Now there are some researches show, polysaccharide and protein-based large biological molecule because its is safe, biodegradable and The advantage, embedding, protection and transmission available for various bioactivators such as stability is strong.
Zeins is as a kind of edible natural phytoprotein, with renewable, nontoxic, amphipathic and good Biocompatibility and degradability, by being self-assembly of microballoon or nano particle, can be usually used in the embedding of function factor with Transmission.But dissolubility of the single zeins colloidal solid in water is poor, to thermo-responsive, this strongly limits it Application in water-soluble food system.Now there are some researches show zeins can pass through noncovalent interaction with polysaccharide Form compound.Such as zeins passes through hydrogen bond, Van der Waals force, hydrophobic interaction shape with chitosan and beet pectin Into composite particles.It is and amphipathic however, focus primarily upon hy-drophilic polysaccharide about the research of zeins and polysaccharide at present The research of polysaccharide interaction still belongs to blank.
Propylene glycol alginate, is to occur the linear polymeric polysaccharide of esterification generation by alginic acid and propane oxide, main Chain is made up of α-L- guluronic acids and beta-D-mannuronic acid, can be with fat because the propylene-glycol-based in molecule is lipophilic end Fat chou is closed, and the uronic acid in molecule is water-wet side, containing great amount of hydroxy group and part carboxyl, can be combined with protein.Therefore, Alginate propylene glycol ester molecule has two kinds of groups of hydrophily and lipophile concurrently, with good surface-active and emulsion stability, fits For dairy products, milk beverage, frozen food etc..The present invention intends preparing compound using zeins and propylene glycol alginate Grain is used to embedding and protecting quercetagetin.
It is the anti-solvent precipitation method, also known as liquid-liquid dispersions method or phase separation currently used for colloidal solid most common method is prepared Method.This method is applied to drip containing a kind of solution of component to prepare colloidal solid in another solution of polarized difference, Organic solution containing two or more components can also be prepared into composite colloid particle using anti-solvent method, this kind of method is referred to as anti-molten Agent coprecipitation, has been used for embedding of the zeins to various bioactivators, such as Quercetin, curcumin and white black false hellebore Alcohol.
The present invention is using zeins, propylene glycol alginate as raw material, using quercetagetin to be representative biological living Property material, using anti-solvent coprecipitation prepare load quercetagetin zeins-propylene glycol alginate be combined Thing.The present invention not only significantly improves the water solubility of quercetagetin, and significantly improves its embedding rate and load capacity, has Effect reduces its light degradation and thermal degradation speed, its bioavailability is significantly improved, while being provided for function factor stable state New way.
The content of the invention
The present invention is low for water-soluble poorly water-soluble, the bioavailability sensitive to light, heat, oxygen of quercetagetin Not enough there is provided a kind of preparation method of large biological molecule compound stable state quercetagetin, it is characterised in that with corn alcohol Molten albumen and propylene glycol alginate are raw material, using quercetagetin as bioactive substance, and legal system is co-precipitated using anti-solvent Zeins-propylene glycol alginate large biological molecule compound of standby load quercetagetin, comprises the following steps:
(1) dissolve:Zeins, propylene glycol alginate, quercetagetin are dissolved in ethanol water simultaneously, Magnetic agitation is to being completely dissolved;
(2) anti-solvent is co-precipitated:The zeins that is obtained step (1) using syringe, propylene glycol alginate and Quercetagetin ethanol water is expelled in distilled water, magnetic agitation in injection process, forms zeins-alginic acid Propylene glycol ester-quercetagetin ternary complex dispersion liquid;
(3) rotary evaporation:Zeins-propylene glycol alginate-quercetagetin three that step (2) is obtained First compound dispersion liquid removes part second alcohol and water using decompression rotary evaporation, prepares ternary complex concentrate;
(4) centrifuge:The ternary complex concentrate that step (3) is obtained, centrifugation removes particle aggregate, obtains ternary and answers Compound seminal fluid;
(5) dry:The ternary complex seminal fluid that step (4) is obtained carries out vacuum freeze drying or spray drying, prepares Go out to load zeins-propylene glycol alginate large biological molecule compound of quercetagetin.
The mass ratio of zeins and propylene glycol alginate described in step (1) is 40:1~1:10, the longevity of quercitrin ten thousand The addition of chrysanthemum element is zeins and 0.1wt%~2.0wt% of propylene glycol alginate quality summation, ethanol water The volume fraction of middle ethanol is 60%~90%.
Injection speed described in step (2) is 5mL/min, mixing speed 200r/min, zeins, alginic acid the third two The volume ratio 1 of alcohol ester and quercetagetin ethanol water and distilled water:10~1:1.
The pressure of decompression rotary evaporation described in step (3) is -0.1MPa, and temperature is 30~60 DEG C, rotary speed 200 ~500r/min, evaporation time is 10~50min, and the ternary complex volume of concentrate is the 1/ of ternary complex dispersion liquid volume 2~1/10.
Centrifugal rotational speed described in step (4) is 3000~6000r/min, and centrifugation time is 10~60min.
The temperature of vacuum freeze drying described in step (5) is -40~-60 DEG C, and the time is 2~10h;Be spray-dried into 150~180 DEG C of material temperature degree, drop temperature is 80 DEG C.
Zeins-propylene glycol alginate large biological molecule of load quercetagetin described in step (5) The embedding rate of quercetagetin is more than 90% in compound, and load capacity is 6.2%~15.4%, effectively reduces its light degradation With thermal degradation speed, hence it is evident that improve its bioavailability.
Beneficial effects of the present invention:The present invention is using natural biological macromolecular zeins and propylene glycol alginate as original Material, using the quercetagetin with the various biological function such as anti-oxidant, anticancer, anti-inflammatory as representative bioactive substance, Zeins-alginate propylene glycol ester complexes of load quercetagetin are prepared using anti-solvent coprecipitation first. The compound is in spongy and with exclusive fruit tree, not only significantly improves the water solubility of quercetagetin, and And its embedding rate and load capacity are significantly improved, its light degradation and thermal degradation speed are effectively reduced, its biological profit is significantly improved With rate.The present invention's is embodied as function factor stable stateization there is provided new way.
Brief description of the drawings
Fig. 1 is that zeins-propylene glycol alginate of anti-solvent coprecipitation preparation load quercetagetin is multiple Compound schematic diagram;
Fig. 2 is the structural representation of zeins-alginate propylene glycol ester complexes of load quercetagetin;Figure Middle 1- zeins;2- propylene glycol alginates;3- quercetagetins;4- loads the molten egg of quercetagetin corn alcohol In vain-alginate propylene glycol ester complexes;5- fruit tree shape micro-structurals;The spongy lyophilized products of 6-.
Embodiment
The invention provides a kind of preparation method of large biological molecule compound stable state quercetagetin, with reference to attached The invention will be further described with embodiment for figure, but not limitation of the present invention.
Embodiment 1
As shown in figure 1, by 0.4g zeins, 0.08g propylene glycol alginates (both mass ratioes 5:1) 20mg quercitrins Patuletin is dissolved in the ethanol solution that 40mL volume fractions are 80%, and magnetic agitation makes it fully dissolve.Will with syringe The above-mentioned solution of 40mL, which is injected into the large beaker for filling 120mL water, does not stop stirring, and mixing speed is 200r/min, is formed muddy Turbid yellow solution, as zeins-propylene glycol alginate-quercetagetin ternary complex dispersion liquid.Using Rotary evaporation concentration ternary complex dispersion liquid is depressurized, pressure is -0.1MPa, and temperature is 40 DEG C, and rotary speed 300r/min steams The hair time is 30min, and the ternary complex volume of concentrate is the 1/4 of ternary complex dispersion liquid volume;Ternary complex is concentrated Liquid centrifugation removes particle aggregate, and the rotating speed 4000r/min of centrifuge, centrifugation time 10min obtain ternary complex seminal fluid; Ternary complex seminal fluid uses vacuum freeze drying, and drying temperature is -50 DEG C, and the time is 6h, obtains load quercetagetin Zeins-alginate propylene glycol ester complexes.
Zeins-propylene glycol alginate compound wall materialses are 93.8% to the embedding rate of quercetagetin, load Measure as 6.2%.After heating 30min through 95 DEG C, the retention rate of the quercetagetin without embedding is 40.21%, and is passed through The retention rate of quercetagetin after zeins-propylene glycol alginate embedding is 96.49%;Through light degradation After 120min, the retention rate of the quercetagetin without embedding is 44.06%, and through zeins-alginate propylene glycol The retention rate of quercetagetin after ester embedding is 85.69%.Therefore, zeins-alginate propylene glycol ester complexes Effectively reduce thermal degradation and the light degradation speed of quercetagetin.
Embodiment 2
As shown in figure 1, by 0.4g zeins, 0.2g propylene glycol alginates (both mass ratioes 2:1) 50mg quercitrins Patuletin is dissolved in the ethanol solution that 40mL volume fractions are 70%, and magnetic agitation makes it fully dissolve.Will with syringe The above-mentioned solution of 40mL, which is injected into the large beaker for filling 200mL water, does not stop stirring, and mixing speed is 500r/min, is formed muddy Turbid yellow solution, as zeins-propylene glycol alginate-quercetagetin ternary complex dispersion liquid.Using Rotary evaporation concentration ternary complex dispersion liquid is depressurized, pressure is -0.1MPa, and temperature is 50 DEG C, and rotary speed 300r/min steams The hair time is 20min, and the ternary complex volume of concentrate is the 1/4 of ternary complex dispersion liquid volume;Ternary complex is concentrated Liquid centrifugation removes particle aggregate, and the rotating speed 4000r/min of centrifuge, centrifugation time 10min obtain ternary complex seminal fluid; Ternary complex seminal fluid ternary complex seminal fluid is using spray drying, and 180 DEG C of feeding temperature, drop temperature is 80 DEG C, is born Carry zeins-alginate propylene glycol ester complexes of quercetagetin.
Zeins-propylene glycol alginate compound wall materialses are 91.7% to the embedding rate of quercetagetin, load Measure as 10.8%.After heating 30min through 95 DEG C, the retention rate of the quercetagetin without embedding is 40.21%, and is passed through The retention rate of quercetagetin after zeins-propylene glycol alginate embedding is 92.19%;Through light degradation After 120min, the retention rate of the quercetagetin without embedding is 44.06%, and through zeins-alginate propylene glycol The retention rate of quercetagetin after ester embedding is 80.52%.Therefore, zeins-alginate propylene glycol ester complexes Effectively reduce thermal degradation and the light degradation speed of quercetagetin.
Embodiment 3
As shown in figure 1, by 0.4g zeins, 0.8g propylene glycol alginates (both mass ratioes 1:2) 100mg quercitrins Patuletin is dissolved in the ethanol solution that 40mL volume fractions are 60%, and magnetic agitation makes it fully dissolve.Will with syringe The above-mentioned solution of 40mL, which is injected into the large beaker for filling 200mL water, does not stop stirring, and mixing speed is 500r/min, is formed muddy Turbid yellow solution, as zeins-propylene glycol alginate-quercetagetin ternary complex dispersion liquid.Using Rotary evaporation concentration ternary complex dispersion liquid is depressurized, pressure is -0.1MPa, and temperature is 55 DEG C, and rotary speed 300r/min steams The hair time is 15min, and the ternary complex volume of concentrate is the 1/4 of ternary complex dispersion liquid volume;Ternary complex is concentrated Liquid centrifugation removes particle aggregate, and the rotating speed 4000r/min of centrifuge, centrifugation time 10min obtain ternary complex seminal fluid; Ternary complex seminal fluid uses vacuum freeze drying, and drying temperature is -50 DEG C, and the time is 6h, obtains load quercetagetin Zeins-alginate propylene glycol ester complexes.
Zeins-propylene glycol alginate compound wall materialses are 84.1% to the embedding rate of quercetagetin, load Measure as 15.4%.After heating 30min through 95 DEG C, the retention rate of the quercetagetin without embedding is 40.21%, and is passed through The retention rate of quercetagetin after zeins-propylene glycol alginate embedding is 82.27%;Through light degradation After 120min, the retention rate of the quercetagetin without embedding is 44.06%, and through zeins-alginate propylene glycol The retention rate of quercetagetin after ester embedding is 75.12%.Therefore, zeins-alginate propylene glycol ester complexes Effectively reduce thermal degradation and the light degradation speed of quercetagetin.
Shown in Fig. 2, propylene glycol alginate is in elongated filamentary structure, zeins particle adsorbed close spherical in shape In fiber surface, quercetagetin is largely embedded in fibrous inside, and small part is embedded by zeins, the compound Just as the fruit tree of the full fruit of a knot, the zeins-alginate propylene glycol ester complexes for loading quercetagetin are dried Afterwards in spongy, the water solubility of quercetagetin is significantly increased.

Claims (7)

1. a kind of preparation method of large biological molecule compound stable state quercetagetin, it is characterised in that with the molten egg of corn alcohol White and propylene glycol alginate is raw material, using quercetagetin as bioactive substance, is prepared using anti-solvent coprecipitation negative Zeins-propylene glycol alginate large biological molecule compound of quercetagetin is carried, is comprised the following steps:
(1) dissolve:Zeins, propylene glycol alginate, quercetagetin are dissolved in ethanol water simultaneously, magnetic force Stirring is to being completely dissolved;
(2) anti-solvent is co-precipitated:Zeins, propylene glycol alginate and the quercitrin for being obtained step (1) using syringe Patuletin ethanol water is expelled in distilled water, magnetic agitation in injection process, forms zeins-alginic acid the third two Alcohol ester-quercetagetin ternary complex dispersion liquid;
(3) rotary evaporation:Zeins-propylene glycol alginate-quercetagetin ternary that step (2) is obtained is answered Compound dispersion liquid removes part second alcohol and water using decompression rotary evaporation, prepares ternary complex concentrate;
(4) centrifuge:The ternary complex concentrate that step (3) is obtained, centrifugation removes particle aggregate, obtains ternary complex Seminal fluid;
(5) dry:The ternary complex seminal fluid that step (4) is obtained carries out vacuum freeze drying or spray drying, prepares negative Carry zeins-propylene glycol alginate large biological molecule compound of quercetagetin.
2. a kind of preparation method of large biological molecule compound stable state quercetagetin according to claim 1, it is special Levy and be, the mass ratio of zeins and propylene glycol alginate described in step (1) is 40:1~1:10, quercitrin marigold The addition of element for zeins and propylene glycol alginate quality summation 0.1wt%~2.0wt%, in ethanol water The volume fraction of ethanol is 60%~90%.
3. a kind of preparation method of large biological molecule compound stable state quercetagetin according to claim 1, it is special Levy and be, injection speed described in step (2) is 5mL/min, mixing speed 200r/min, zeins, alginic acid the third two The volume ratio 1 of alcohol ester and quercetagetin ethanol water and distilled water:10~1:1.
4. a kind of preparation method of large biological molecule compound stable state quercetagetin according to claim 1, it is special Levy and be, the pressure of the decompression rotary evaporation described in step (3) is -0.1MPa, and temperature is 30~60 DEG C, rotary speed 200 ~500r/min, evaporation time is 10~50min, and the ternary complex volume of concentrate is the 1/ of ternary complex dispersion liquid volume 2~1/10.
5. a kind of preparation method of large biological molecule compound stable state quercetagetin according to claim 1, it is special Levy and be, centrifugal rotational speed described in step (4) is 3000~6000r/min, centrifugation time is 10~60min.
6. a kind of preparation method of large biological molecule compound stable state quercetagetin according to claim 1, it is special Levy and be, the temperature of the vacuum freeze drying described in step (5) is -40~-60 DEG C, and the time is 2~10h;Be spray-dried into 150~180 DEG C of material temperature degree, drop temperature is 80 DEG C.
7. a kind of preparation method of large biological molecule compound stable state quercetagetin according to claim 1, it is special Levy and be, zeins-propylene glycol alginate large biological molecule of the load quercetagetin described in step (5) The embedding rate of quercetagetin is more than 90% in compound, and load capacity is 6.2%~15.4%, effectively reduces its light degradation With thermal degradation speed, hence it is evident that improve its bioavailability.
CN201710206621.9A 2017-03-31 2017-03-31 A kind of preparation method of large biological molecule compound stable state quercetagetin Pending CN106983871A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710206621.9A CN106983871A (en) 2017-03-31 2017-03-31 A kind of preparation method of large biological molecule compound stable state quercetagetin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710206621.9A CN106983871A (en) 2017-03-31 2017-03-31 A kind of preparation method of large biological molecule compound stable state quercetagetin

Publications (1)

Publication Number Publication Date
CN106983871A true CN106983871A (en) 2017-07-28

Family

ID=59414656

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710206621.9A Pending CN106983871A (en) 2017-03-31 2017-03-31 A kind of preparation method of large biological molecule compound stable state quercetagetin

Country Status (1)

Country Link
CN (1) CN106983871A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109212094A (en) * 2018-10-30 2019-01-15 晨光生物科技集团股份有限公司 The detection method of quercetagetin in marigold residue
CN109805375A (en) * 2019-01-28 2019-05-28 集美大学 A kind of functional food and preparation method thereof improving organum visuale's oxidation resistance
CN113621440A (en) * 2020-05-06 2021-11-09 晨光生物科技集团股份有限公司 Grease composition with better stability
CN114098076A (en) * 2021-11-18 2022-03-01 江南大学 Preparation method of genipin-crosslinked quercetin-zein/pectin/chitosan nanoparticles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104225669A (en) * 2014-08-25 2014-12-24 华南理工大学 Bioactive bacterial cellulose-zein composite film and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104225669A (en) * 2014-08-25 2014-12-24 华南理工大学 Bioactive bacterial cellulose-zein composite film and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CUIXIA SUN ET AL.: "Binary Complex Based on Zein and Propylene Glycol Alginate for Delivery of Quercetagetin", 《BIOMACROMOLECULES》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109212094A (en) * 2018-10-30 2019-01-15 晨光生物科技集团股份有限公司 The detection method of quercetagetin in marigold residue
CN109212094B (en) * 2018-10-30 2021-03-30 晨光生物科技集团股份有限公司 Method for detecting quercitin in marigold dregs
CN109805375A (en) * 2019-01-28 2019-05-28 集美大学 A kind of functional food and preparation method thereof improving organum visuale's oxidation resistance
CN113621440A (en) * 2020-05-06 2021-11-09 晨光生物科技集团股份有限公司 Grease composition with better stability
CN114098076A (en) * 2021-11-18 2022-03-01 江南大学 Preparation method of genipin-crosslinked quercetin-zein/pectin/chitosan nanoparticles

Similar Documents

Publication Publication Date Title
CN106983871A (en) A kind of preparation method of large biological molecule compound stable state quercetagetin
Li et al. Controlled release system by active gelatin film incorporated with β-cyclodextrin-thymol inclusion complexes
Xiao et al. Maltodextrin as wall material for microcapsules: A review
Tavassoli-Kafrani et al. Encapsulation of orange essential oil using cross-linked electrospun gelatin nanofibers
Jia et al. Encapsulation of phenolic compounds present in plants using protein matrices
Guo et al. Starch-based materials encapsulating food ingredients: Recent advances in fabrication methods and applications
Wani et al. Suitability of different food grade materials for the encapsulation of some functional foods well reported for their advantages and susceptibility
CN106822035A (en) A kind of zeins shellac curcumin composite colloid particle and preparation method thereof
Weisany et al. Targeted delivery and controlled released of essential oils using nanoencapsulation: A review
Premjit et al. Current trends in flavor encapsulation: A comprehensive review of emerging encapsulation techniques, flavour release, and mathematical modelling
CN107712543B (en) Anti-flocculation curcumin microcapsule, preparation method and application thereof
Farahani et al. Modification of sodium alginate by octenyl succinic anhydride to fabricate beads for encapsulating jujube extract
Vidal J et al. Microencapsulation of maqui (Aristotelia chilensis Molina Stuntz) leaf extracts to preserve and control antioxidant properties
Zhao et al. Research progress of starch as microencapsulated wall material
CN104436205A (en) Nano carrier prepared from marine sulfated polysaccharide, nano complex and application of nano carrier
Alexandre et al. Cross-linked coacervates of cashew gum and gelatin in the encapsulation of pequi oil
Aghajanzadeh et al. Hornification: Lessons learned from the wood industry for attenuating this phenomenon in plant‐based dietary fibers from food wastes
Tao et al. A review on the chemical modification of alginates for food research: Chemical nature, modification methods, product types, and application
CN114081096A (en) Preparation method of milk protein loaded astaxanthin emulsion combined with polyphenol and glycosylation modification
English et al. Flavour encapsulation: A comparative analysis of relevant techniques, physiochemical characterisation, stability, and food applications
Nurhadi et al. The virgin coconut oil (VCO) emulsion powder characteristics: effect of pickering emulsion with microcrystalline cellulose (MCC) and different drying techniques
Yuan et al. Efficient utilization of tea resources through encapsulation: Dual perspectives from core material to wall material
CN111468050A (en) Method for preparing composite essential oil particles based on microfluidic technology
Shahidi et al. Food and bioactive encapsulation
Sharkawy et al. Plant gums in Pickering emulsions: A review of sources, properties, applications, and future perspectives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170728

WD01 Invention patent application deemed withdrawn after publication